功能性肠病全球患病率、特征及影响
基于罗马基金会全球流行病学研究26国互联网数据,罗马IV标准下功能性肠病患病率为33.2%,以便秘型最常见(11.7%)。功能性肠病患者非胃肠道躯体症状和心理症状更多、生活质量更差、医疗利用更高,且全球各地区结果相似。
要点
- 罗马IV标准下功能性肠病全球患病率为33.2%,功能性便秘最常见(11.7%)。
- 功能性肠病与更多非胃肠道躯体症状、心理症状、生活质量下降和医疗利用增加相关。
- 罗马IV较罗马III的肠易激综合征患病率降低(4.1% vs 10.1%),主要因腹痛频率阈值改变。
核心结论
- 功能性肠病全球常见,地区和国家间差异小,对健康和日常生活有显著影响。
研究设计与样本
- 基于罗马基金会全球流行病学研究26国互联网数据的横断面研究,并在14国分析罗马III与罗马IV肠易激综合征标准变化的影响。
主要发现
- 罗马IV标准下任何功能性肠病患病率为33.2%,功能性便秘最常见(11.7%),其次为未指定功能性肠病(8.7%)。
- 未指定功能性肠病最常见的合格症状是排便习惯改变,腹痛对健康负面影响贡献尤其大。
- 功能性肠病患者非胃肠道躯体症状和心理症状更多、生活质量降低、医疗利用增加,在肠易激综合征和阿片类药物所致便秘中最明显。
- 全球各地区和国家间结果相似;罗马IV较罗马III的肠易激综合征患病率降低(4.1% vs 10.1%),主要因腹痛和/或不适的症状频率阈值改变。
关键数值与推荐
- 罗马IV标准下任何功能性肠病患病率为33.2%。
- 功能性便秘患病率为11.7%,未指定功能性肠病为8.7%。
- 罗马IV肠易激综合征患病率为4.1%,罗马III为10.1%。
临床怎么用
- 临床评估功能性肠病时需关注非胃肠道躯体症状、心理症状及生活质量下降。
- 肠易激综合征诊断标准版本变化可显著影响患病率,解读流行病学数据时需注意标准差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Functional bowel disorders (FBDs) are common and have a profound impact on many aspects of life. However, little is known about their prevalence and impact in different parts of the world. METHODS: We used internet data (26 countries) from the Rome Foundation Global Epidemiology Study to define the current prevalences of FBD and the association with psychological and nongastrointestinal somatic symptoms, quality of life, demographics, medical history, and healthcare utilization. We also investigated effects of changes in irritable bowel syndrome (IBS) criteria from Rome III to IV in 14 countries. RESULTS: Rome IV criteria for any FBD were fulfilled by 33.2%, with functional constipation being the most common diagnosis (11.7%) followed by unspecified FBD (8.7%). Altered bowel habits was the most common qualifying symptom for unspecified FBD, while abdominal pain contributed particularly to the negative health impact. Individuals with FBD had more nongastrointestinal somatic and psychological symptoms, reduced quality of life, and increased healthcare utilization, most pronounced in IBS and opioid-induced constipation. Findings were similar across world regions and countries. The major contributor to lower Rome IV, vs Rome III, IBS prevalence (4.1% vs 10.1%) was the change in symptom frequency threshold for abdominal pain and/or discomfort. Minor alterations in IBS criteria influenced prevalence rates, but all versions showed associations with deleterious health impact. DISCUSSION: FBDs are common globally with minor differences across regions and countries and with prominent effects on health and daily life. Relatively minor diagnostic criteria changes can affect IBS prevalence rates substantially, but the negative health impact remains.
引用
- Tornkvist NT, Palsson OS, Hreinsson J, et al. Global Prevalence, Characterization, and Impact of Functional Bowel Disorders. Am J Gastroenterol. 2025. PMID: 41020663. doi:10.14309/ajg.0000000000003782
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。